Saltar al contenido

Compounded GLP-1 Recall and 'Research Use' Retatrutide Put Unapproved Weight-Loss Drugs Under Scrutiny

23 de octubre de 2026 · 22 min

Notas del episodio

Unapproved GLP-1 drugs are under pressure from several directions. Compounding pharmacy Apothecary Pharma voluntarily recalled 22 lots of compounded tirzepatide, the active ingredient in Zepbound and Mounjaro, citing "lack of assurance of sterility," and FDA classified the recall as Class II. A bipartisan group of senators led by Sen. Jim Banks wrote to the acting FDA commissioner on October 14, 2026, urging a crackdown on vendors using "for research use only" labels to sell retatrutide, Eli Lilly's investigational drug that is not FDA-approved, and citing a 265% rise in poisonings tied to illicit retatrutide reported by America's Poison Centers. CBS News reported that FDA received two adverse-event reports of deaths linked to products sold as retatrutide; the reports are unverified and do not prove the products caused the deaths. We also walk through FDA's own warnings: compounded drugs are not FDA-approved, retatrutide cannot be used in compounding, and FDA has flagged quality problems at overseas ingredient suppliers. We explain how compounded, counterfeit and "research use only" products differ from FDA-approved medicines, and what regulators, lawmakers and drugmakers are doing about them. Sources: - FDA, "FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss" (updated Oct 1, 2026): https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss - Sen. Jim Banks press release and senators' letter to FDA (Oct 15, 2026): https://www.banks.senate.gov/news/press-releases/banks-urges-fda-to-crack-down-on-illicit-research-use-only-drugs/ - CBS News, reported deaths and bootleg retatrutide: https://www.cbsnews.com/news/deaths-reported-fda-bootleg-reta-weight-loss-drug/ - BioPharma Dive, Apothecary Pharma compounded tirzepatide recall (Oct 22, 2026): https://www.biopharmadive.com/news/glp1-obesity-drug-recall-apothecary-tirzepatide-zepbound/833712/ - USA TODAY, compounded GLP-1 recall and FDA actions (Oct 20, 2026): https://www.usatoday.com/story/money/personal-finance/healthcare/2026/10/20/fda-targets-copycat-glp-1-weight-loss-drugs/92343423007/ Cover photo: laboratory at the FDA White Oak campus, Building 64 (U.S. Food and Drug Administration, public domain, via Wikimedia Commons; cropped). This show is for information only and is not medical advice. Always talk to your doctor before starting, stopping, or changing any medication. More at glp1newspaper.com

Todos los episodios de GLP-1 Newspaper: Daily Ozempic, Zepbound & Weight-Loss Drug News

Ajustes

Visualización

Idioma

Determina qué emisoras ves primero en la página de inicio.

Historial

Las emisoras y episodios escuchados recientemente y tus últimas búsquedas solo se guardan en este navegador.

Avisos

Un breve aviso cuando un pódcast que sigues tiene un episodio nuevo. Puedes desactivar pódcast concretos con la campana de su página.

Cuenta

Guarda tus favoritos: en la app y en la web.

Atajos de teclado

/
Abrir búsqueda
Espacio
Reproducir o pausar
← →
En el reproductor: 15 s atrás, 30 s adelante (episodios) · en una fila: siguiente tarjeta
↑ ↓
En una fila: destino dentro de la tarjeta
Inicio / Fin
En una fila: primera o última tarjeta
Esc
Cerrar ventana o menú
?
Este resumen
Reproduciendo ahora

Ir a la emisora

A continuación

    Añade episodios con «A continuación»: sonarán después del episodio actual.